Homepage > Company > Media > Pharma News > 2022 > Myovant Sciences Rejects $2.5 Billion Takeover Offer From Sumitovant, Sumitomo

Myovant Sciences Rejects $2.5 Billion Takeover Offer From Sumitovant, Sumitomo

UK-based Myovant Sciences has rejected a $2.5 billion takeover bid from Sumitovant Biopharma and its parent company Sumitomo Pharma.

Sumitovant already holds approximately 52 percent of Myovant’s shares of the company, but Myovant says the purchase offer undervalues the remaining shares.

In August, the FDA expanded its approval of Pfizer and Myovant’s oral drug Myfembree (relugolix, estradiol and norethindrone acetate) to include the management of moderate-to-severe pain associated with endometriosis in premenopausal women, with a treatment duration of up to 24 months.

The drug combines relugolix, a gonadotropin-releasing hormone receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin.

Myfembree is also approved for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

October 4, 2022

https://www.fdanews.com/

Read also

UK and US agree on landmark pharma pricing tariff deal

The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.

Parkinson's drug as basis for new anti-infectives

Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.

Modified herpes virus helps destroy glioblastoma in preclinical models

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms

Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant pr...